A computer implemented method, system, and non-transitory computer-readable device for implementing a generalized metadata generation system for omics data is provided. In some embodiments, a generalized reconstruction model may be trained to perform anomaly detection on an unlabeled omics feature vector. Various embodiments provide generalized anomaly detection that are agnostic to specific organs or exposure groups through aggregating and preprocessing omics data from disparate datasets. The generalized metadata generation system may then generate and assign an anomalous or non-anomalous label as metadata to improve computational interpretability of omics data.
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
2.
METHOD AND SYSTEM FOR DELIVERY OF THERAPEUTICS TO EYE
A surgical instrument is provided for delivery of therapeutic agents into an eye. The instrument includes a cannula that is connected to a handle of the instrument and through which therapeutic agents are delivered into the eye via a continuous and controlled infusion. In certain aspects, a sheath which has a diameter greater than that of the cannula accommodates the cannula therein. An insertion tip is formed at a distal end of the cannula to penetrate tissue of the eye at a tangential angle.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
3.
TARGETING AN EUKARYOTIC INITIATION FACTOR 2 ALPHA KINASE TO REGULATE TRANSLATION UNDER STRESS
The identification of a direct kinase of eukaryotic initiation factor 2 alpha (eIF2α), microtubule affinity-regulating kinase 2 (MARK2), which phosphorylates eIF2α in response to proteotoxic stress, is provided. Inhibitors of MARK2 and their use in treating neurodegenerative disease, including Alzheimer's disease, Parkinson disease, Creutzfeldt-Jakob disease, Huntington's disease, frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS), also are disclosed.
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
C07C 237/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
C07D 233/36 - One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
Producing an ordered graphitic carbon includes contacting a material including disordered elemental carbon and a metal with chlorine gas, thereby yielding a gaseous product comprising a chloride of the metal and a solid product comprising the ordered graphitic carbon.
The present invention is in the field of carbon dioxide capture, in particular the capture of carbon dioxide directly from air or some other emission source. The invention concerns a device and a process for the capture of carbon dioxide, from air or some other emission source, using hydroxide solutions as the sorbent.
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
B01D 53/22 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or propertiesManufacturing processes specially adapted therefor characterised by their properties
The present disclosure relates to multi-principal element alloy (MPEA) nanoparticles and the synthesis of said MPEA nanoparticles in organic solutions. The present disclosure also relates to catalysts comprising the MPEA nanoparticles for use, for example, in fuel cells and water electrolyzers.
B22F 9/24 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
C22C 5/04 - Alloys based on a platinum group metal
C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α) and their use in imaging and treating FAP-α related diseases and disorders are disclosed.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Techniques for natural language control of an imaging device are presented. The techniques use an imaging device interface, a language model interface, an audio interface, and a human model. The audio interface receives an audio input from a user, transcribes the audio input, and provides the audio input transcription to the language model interface. The language model interface provides the audio input transcription to the language model, receives a response from the language model, and provides the response to the human model. The human model maintains a representation of a current position of an individual, receives the response from the language model interface, forms an action request based on the response and the current position of the individual, and sends the action request to imaging device interface. The imaging device interface sends the action request to the imaging device, such that the imaging device acts on the action request.
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof) of formula (I), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier. Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activitye. This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods of using same for the treatment of systemic diseases of the body.
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof) of formula (I), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier. Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activitye. This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods of using same for the treatment of systemic diseases of the body.
Improved hypotonic gelling vehicles are described as solubilizing agents for drugs and as a means to provide sustained drug delivery to the eye. It has been discovered that the addition of small amounts of low molecular weight PEG to hypotonic gel-forming compositions enhances the viscosity of the solution at the ocular surface, prologs tear break-up time and increases ocular comfort. Solubilizing drugs at higher concentrations enhances drug penetration into the tissues of the body, while the hypotonic gelling vehicle further improves distribution of the drug over a larger surface area for increased absorption and sustained release for reduced side effects and longer duration of action.
According to various embodiments, a system for, and method of, presenting olfactory stimuli for olfactory dysfunction testing and training is disclosed. The system includes an integrated device. The integrated device includes: a plurality of scent chambers, where each scent chamber includes a respective material having a corresponding scent, such that the plurality of scent chambers include a plurality of different materials having a corresponding plurality of different scents. The integrated device is operable to selectively expose an aperture of an individual scent chamber, such that a corresponding scent of a corresponding material in the individual scent chamber is exposed for sampling by a user.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
C07C 259/06 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
C07J 41/00 - Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/06 - Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
13.
MIR-211 AND ACSL4 AS THERAPEUTIC AGENTS FOR CHILDHOOD CANCER MEDULLOBLASTOMAS
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC (USA)
Inventor
Perera, Ranjan J.
Rangaramanujam, Kannan
Hanes, Justin
Seal, Sudipta
Abstract
Nanoparticles comprising miR-211 and their use for treating brain cancers, such as medulloblastomas, including pediatric medulloblastomas, are disclosed.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
C07C 275/16 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
C07C 275/18 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
A polymer having the structure N+ Ar is a N-containing monocyclic or bicyclic aromatic ring having 1 or 2 N atoms, at least one of the N atoms is substituted with Ra to have a positive charge and the ring is optionally substituted with Rb, Ra is H, thiophene, furan, pyridine, benzene, thiazole, C1-C12 alkyl optionally substituted with one or more F atoms, or polyoxyethylene (—(CH2CH2O)n—H and Rb is H, C1-C12 alkyl, aralkyl, or C1-C12 alkoxy. Ar is a phenyl or naphthalene ring, optionally substituted with Rc or CO2Ph. Any of the phenyl or naphthalene rings is substituted with Rc which is H, C1-C12 alkyl, or C1-C12 alkoxy, and Rd is H or Me. X is halogen, bicarbonate (HCO3−), carbonate, bisulfate (HSO4−), bisulfite (HSO3−), methane sulfonate (MeSO3−). triethyl borohydride (Et3BH−) or a C1-C6 carboxylate. The ratio of x:y is from about 99:1 to about 1:99.
C08L 65/00 - Compositions of macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chainCompositions of derivatives of such polymers
H10K 10/46 - Field-effect transistors, e.g. organic thin-film transistors [OTFT]
A system for pacing a heart of a patient includes a wire having a first end and a second end. The first end is configured to be connected to a pulse generator. The second end includes one or more connectors. The system also includes one or more anchors that are configured to be attached to the heart of the patient. The one or more connectors are configured to be releasably connected to the one or more anchors. The pulse generator is configured to transmit electrical pulses through the wire and the one or more connectors to the heart to pace the heart after a cardiac surgery.
Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off-target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.
Methods for treating a neurodegenerative disease in a subject in need of treatment thereof comprising restoring TDP-43 function in neurons of the subject. The restoring of TDP-43 function includes repairing nuclear pore complex (NPC) injury, which can include increasing expression of nucleoporin POM121.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
The identification of mutations that are present in a small fraction of DNA templates is essential for progress in several areas of biomedical research. Though massively parallel sequencing instruments are in principle well-suited to this task, the error rates in such instruments are generally too high to allow confident identification of rare variants. We here describe an approach that can substantially increase the sensitivity of massively parallel sequencing instruments for this purpose. One example of this approach, called “Safe-SeqS” for (Safe-Sequencing System) includes (i) assignment of a unique identifier (UID) to each template molecule; (ii) amplification of each uniquely tagged template molecule to create UID-families; and (iii) redundant sequencing of the amplification products. PCR fragments with the same UID are truly mutant (“super-mutants”) if ≥95% of them contain the identical mutation. We illustrate the utility of this approach for determining the fidelity of a polymerase, the accuracy of oligonucleotides synthesized in vitro, and the prevalence of mutations in the nuclear and mitochondrial genomes of normal cells.
In one aspect, a magnetic actuation system for tissue engineering is provided. A preferred includes a) a magnetic substrate; and b) a magnetic field source adapted for dynamic application of a magnetic field to the magnetic substrate
G01N 33/483 - Physical analysis of biological material
A61B 5/243 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetocardiographic [MCG] signals
A61B 5/248 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoneurographic [MNG] signals, e.g. magnetospinographic [MSG] signals
C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
An analysis system for a translucent bodily fluid includes a flow chamber for the translucent bodily fluid defining an imaging section therein, an illumination source arranged to provide illumination light to said imaging section of said flow chamber, an optical sensor arranged proximate to said flow chamber and arranged to receive light after passing through said flow chamber, said optical sensor providing detection signals, and a processor arranged to communicate with said optical sensor to receive said detection signals therefrom. The illumination source provides at least partially coherent light to said imaging section of said flow chamber such that said detection signals correspond to a two-dimensional image, and the processor is configured to extract information from said two-dimensional image for particles when present within the translucent bodily fluid passing through said flow chamber.
G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
G01N 15/1433 - Signal processing using image recognition
In one aspect, compositions are provided for the simultaneous in situ quantification and localization of RNA sequences with subcellular precision are utilized in the methods. In particular, specific hybridization of at least one probe set in a sample is followed by in situ ligation, which locks specifically circularized probe set around an RNA target sequence. Rolling circle amplification followed by fluorescently labeled detector probe hybridization, enables simultaneous in situ quantification and localization of RNA sequences with subcellular precision.
Disclosed herein is an electro-synthesizer unit comprising a first compartment comprising a cathode and a first electrolyte, a second compartment comprising an anode and a second electrolyte and a third compartment comprising a third electrolyte. The unit is configured to produce acid and base solution at desired concentrations. Also disclosed are methods of using the electro-synthesizer unit and producing the acid and base solution at desired concentrations.
C25B 9/21 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms two or more diaphragms
The present invention provides methods for preventing or reducing degeneration of dopaminergic neurons and/or preventing or ameliorating at least one motor deficit in a subject in need thereof, such as in a subject with α-synucleinopathy, using agents that modulate Fndc5 or biologically active fragments thereof, such as irisin.
A 2D x-ray system includes an x-ray illumination system constructed to illuminate an object with an x-ray beam, a detection system arranged to receive at least a portion of said x-ray beam after passing through at least a portion of said object, and a system for registering a 2D x-ray image to a 3D x-ray image. The system includes a computer processor and computer memory that includes non-transient code, which when executed by said computer processor causes the computer processor to perform a method that includes generating multiple 2D projection images from a 3D x-ray image of the object, and registering said 2D x-ray image to one of said 2D projection images. Said registering uses a similarity metric that is differentially weighted to affect an influence of at least one of low-contrast or high-contrast structures on the registering between said 2D x-ray image and each of said 2D projection images.
Disclosed are dimeric copper centers supported on graphitic carbon nitride (denoted herein as Cu2@C3N4) and their use as advanced catalysts for partial oxidation of CH4.
C07C 29/50 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by oxidation reactions with formation of hydroxy groups with molecular oxygen only
Disclosed herein are compositions, devices, and methods for producing lithium hydroxide by electrochemical extraction of lithium from lithium-containing solutions, including unconventional sources that have low lithium content, such as brine and seawater.
C25B 1/46 - Simultaneous production of alkali metal hydroxides and chlorine, oxyacids or salts of chlorine, e.g. by chlor-alkali electrolysis in diaphragm cells
C25B 9/19 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms
C25B 11/097 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds comprising two or more noble metals or noble metal alloys
C25B 13/05 - DiaphragmsSpacing elements characterised by the material based on inorganic materials
C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes
28.
System and Method for Annotating Pathology Images to Predict Outcome
Methods, systems, apparatus, and computer programs, for predicting clinical outcome of a patient. In one aspect, a method includes obtaining a pathology image associated with the patient; processing the pathology image including: determining a region of interest of the pathology image; and segmenting the pathology image into a plurality of tiles, wherein the plurality of tiles has a uniform size; providing the processed pathology image as an input to a machine learning model configured to annotate the pathology image and predict the clinical outcome of the patient based on the annotated pathology image; obtaining, as an output of the machine learning model, the annotated pathology image associated with the patient, wherein the annotated pathology image includes annotations for different classes of tissues including a tumor regression; and determining, based on the annotated pathology image, a metric indicative of the clinical outcome of the patient.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
G06V 20/70 - Labelling scene content, e.g. deriving syntactic or semantic representations
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
Disclosed herein are systems and methods of capturing orbital and sub-orbital extraterrestrial debris. The system is directed to a pouch comprising a semi-penetrable outer fabric covering a debris particle-capturing core. Also disclosed herein are methods of producing the pouch. Further described herein are methods of capturing debris with a deployed pouch.
Disclosed herein are systems and methods for improving thin film thermoelectric fabrication and performance. A method for fabricating a thin film thermoelectric device includes coupling an n-type structure and a p-type structure to a first header. The method may also include positioning, by at least two force points, a first end and a second end of the n-type structure to the first header and positioning, by at least two force points, a first end and a second end of the p-type structure to the first header. The method may also include bonding the n-type structure and the p-type structure to the first header. The n-type or p-type structure contains epitaxially grown contact layers. For example, a p-type structure includes a p-type material sandwiched between two heavily doped p+ layers. Similarly, an n-type structure includes an n-type material sandwiched between two heavily doped n+ layers.
H10N 10/10 - Thermoelectric devices comprising a junction of dissimilar materials, i.e. devices exhibiting Seebeck or Peltier effects operating with only the Peltier or Seebeck effects
Disclosed herein are systems and methods of manufacturing thermoelectric thin film periodic materials, structures, and devices. In some embodiments, the thermoelectric thin film periodic structure can be grown on the (111) plane of a substrate. In some embodiments, the thermoelectric thin film periodic structure can include a hexagonal rhombohedral crystalline microstructure and a controlled hierarchically engineered superlattice structure disposed along a growth axis of a substrate having a long-range uniform periodicity. In some embodiments, the thermoelectric thin film periodic structure can be grown at a temperature ranging from about 300°C to about 450 °C. In some embodiments, the thermoelectric thin film periodic structure can be grown on a heavily doped portion of a substrate.
A method of producing a population of mature human pluripotent stem cell-derived sensory neurons (hPSC-SNs) expressing a target gene associated with at least one of nociceptive pain, chronic pain, pruriception and a nociceptive- or pruriceptive- mediated condition, the method comprising introducing into a population of human pluripotent stem cells (hPSCs) a composition comprising at least one site-directed nuclease targeting a site within the target gene, and at least one nucleic acid comprising a nucleotide sequence encoding at least one screenable, selectable marker that is flanked by (i) a nucleotide sequence homologous with a region located upstream of the target site within the target gene and (ii) a nucleotide sequence homologous with a region located downstream of the target site within the target gene, wherein the target site is located downstream of the open reading frame of the target gene, and wherein the site-directed nuclease cleaves the target site of the target gene and the nucleic acid encoding the screenable, selectable marker is inserted at the target site; covering said population of hPSCs under an extracellular matrix comprising at least one neuronal differentiation driver to produce a sensory committed neural crest population; contacting said sensory committed neural crest population with at least one neuronal differentiation driver and at least one neurotrophic factor to produce a population of early sensory neurons (SNs); and contacting said population of early SNs with at least one neurotrophic factor to produce a population of mature hPSC-SNs expressing at least one of SN marker or one pan neuronal marker; isolating the cells expressing the at least one screenable, selectable marker, wherein said population of mature hPSC-SNs expressed said one target gene associated with nociceptive pain, chronic pain, pruriception a nociceptive- or pruriceptive- mediated condition, and wherein said population of mature hPSC-SNs responds to a nociceptive and pruriceptive stimulus.
Methods, and related compositions. for the improved synthesis of [18F]DCFPyL are disclosed. Also provided are methods, and related compositions. for the use of [18F]DCFPyL so produced.
A system for and method of autonomously robotically acquiring an ultrasound image of an organ within a bony obstruction of a patient is presented. The techniques include acquiring an electronic three-dimensional patient-specific representation of the bony obstruction of the patient; obtaining an electronic representation of a target location in or on the organ within the bony obstruction of the patient; determining, automatically, position and orientation of an ultrasound probe to acquire an image of the target location; and directing, autonomously, and by a robot, the ultrasound probe on the patient to acquire the image of the target location based on the position and orientation.
Disclosed herein are compositions containing a mixture of an soluble fraction and insoluble fraction derived from at least one helminth egg for use in treating wounds and/or injuries to tissues in subjects in need of treatment thereof.
Disclosed herein is an electro-synthesizer unit comprising a first compartment comprising a cathode and a first electrolyte, a second compartment comprising an anode and a second electrolyte and a third compartment comprising a third electrolyte. The unit is configured to produce acid and base solution at desired concentrations. Also disclosed are methods of using the electro-synthesizer unit and producing the acid and base solution at desired concentrations. Also disclosed are systems for direct capturing of carbon dioxide. Also disclosed are mining systems utilizing the disclosed herein electro-synthesizer units.
This disclosure describes novel methods and systems for discriminating between tumor-origin variants and clonal hematopoiesis (CH)-derived variants across solid tumors and NGS sequencing platforms. The disclosed methods and systems utilize a machine learning model that integrates fragment-level, vanant-level, and patient-level features, allowing for predicting tumor vs. CH variant origin using plasma-only sequencing without additional white blood cell (WBC) or tumor sequencing. The ability to identify bona fide tumor- derived variants in plasma-only sequencing fills a critical need in the clinical implementation of liquid biopsy-guided cancer therapy by reducing misinterpretation due to CH contamination. The methods and systems as disclosed have improved precision and reliability' of prediction utilizing circulating-tumor DNA (ctDNA) for clinical prognosis purposes.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A new simplified method for the production of the radiopharmaceutical agent 111InIn-XYIMSR-01 is disclosed. The presently disclosed method significantly increases accessibility to the pharmaceutical as it can now be produced at any radiopharmacy without the need for specialized equipment.
A61K 51/02 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
39.
A METHOD AND SYSTEM FOR PREDICTING ANEURYSMAL OCCLUSION RESULTING FROM FLOW DIVERTING STENTS
Aneurysmal occlusion prediction resulting from stents, and flow diverting stents in particular, is determined using the system and the method of the present invention. The system utilizes existing or new patient data, such as imaging data, vitals, heart rate, and medications, in conjunction with a vessel segmentation algorithm to model outcomes for the patient. The system can be used to evaluate a specific stent choice for the patient, evaluating anticoagulation therapy for a patient with a flow diverter, and evaluating optimal stent design for a patient.
A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Systems and methods for detection and localization of a foreign body object in a region are provided. In embodiments, a system can a processor and one or more computer-readable storage media storing instructions which, when executed on the processor, cause the processor to perform a method for forming a trained model using a plurality of training images and a plurality of training boundary data sets. The systems and methods further apply the trained model to process an image and generate a boundary data set. In embodiments, the image can be an ultrasound image, and the boundary data set can correspond to a bounding box enclosing the foreign body object.
Provided herein is technology relating to nucleotide repeat elements present in the genomes of eukaryotes and particularly, but not exclusively, to technologies for reducing the levels of disease-causing products expressed from expansions of nucleotide repeats.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12N 15/52 - Genes encoding for enzymes or proenzymes
43.
PATHOGEN DETECTION AND IDENTIFICATION SYSTEM AND METHOD
A pathogen detection system and method are disclosed. The pathogen detection system includes a pathogen sensor comprising a plasmonically active pathogen sensing area that comprises a hybrid structure of electrically conductive surface and metal nanofractals, forming a surface enhanced Raman spectroscopic (SERS) substrate and a controller comprising a memory storing one or more trained machine learning algorithms, that perform label-free identification and differentiation of a pathogen or the pathogen and a pathogen mutation based on acquired Raman spectra.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
44.
RECOMBINANT ANTIBODIES COMPRISING ANTI-HUMAN IMMUNOGLOBULIN G-INVERTASE FUSION PROTEINS AND METHODS OF USING THE SAME
The present disclosure relates to recombinant antibodies comprising anti-human immunoglobulin G (IgG)-invertase fusion proteins (also called “recombinant antibody fusion proteins”), kits comprising the same, and methods of using the same. The recombinant antibody fusion proteins permit detection of antibodies to a broad array of antigenic polypeptides, such as a polypeptide of an infectious pathogen or a human polypeptide known to associate with autoimmune diseases or disorders in a quick, reliable, and affordable immunoassay using personal glucometers.
C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
C12Q 1/40 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving amylase
C12Q 1/54 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving glucose or galactose
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
THE JOHNS HOPKINS UNIVERSITY (USA)
Inventor
Wipf, Peter
Montoya, Adam Patrick
Hackam, David
Sodhi, Chhinder
Lu, Peng
Abstract
Novel compounds and methods of using the compounds are provided herein. The compounds include novel carbon analogs of pyranose derivatives discovered to have Toll-like receptor 4 (Tlr4) inhibitory activity. The methods provide for treating infectious, inflammatory and post-traumatic disorders.
A method and system is disclosed for analyzing image data of a subject. The image data can be collected with an imaging system in a selected manner and/or motion. The image data may include selected overlap and be acquired with an imaging system that generates a plurality of perspectives for more than one location. An automatic system and method may then define or identify various features and/or allow for registration for alternative image data.
G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
G06T 5/50 - Image enhancement or restoration using two or more images, e.g. averaging or subtraction
G06V 10/22 - Image preprocessing by selection of a specific region containing or referencing a patternLocating or processing of specific regions to guide the detection or recognition
G06V 10/25 - Determination of region of interest [ROI] or a volume of interest [VOI]
G06V 10/40 - Extraction of image or video features
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
G06V 10/764 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using classification, e.g. of video objects
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
47.
USE OF ACRYLIC ACID-CONTAINING POLYMERS FOR MOLECULAR IMAGING OF TARGET PROTEINS
Acrylic acid-containing polymers that can be used as MRI agents, and condensation reactions for producing same is described herein. Condensation reactions can be used to attach a number of MRI signal-generating molecules and targeting molecules to the polymer, wherein the targeting molecule binds a molecular target of interest such as a cancer biomarker. Advantageously, the acrylic acid-containing polymers provide multiple attachment sites for the MRI signal-generating molecule, enabling an increase in the number of less toxic and less immunogenic MRI signal-generating molecules to detectable levels.
Examples may provide a method of determining a neurological disorder status of a subject. The method includes generating at least one dynamic brain network model (DNM) for the subject, and determining at least one sink index (SI) for the subject using the DNM. The method also includes determining whether the subject has frontotemporal dementia (FTD), Alzheimer's disease, or does not have dementia using one or more SI ratios of brain regions associated with FTD to other brain regions. Additional methods as well as related systems and computer readable media are also provided.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
49.
ROTATIONAL FREEFORM STIMULATOR AND MULTICHANNEL FREEFORM STIMULATOR
A rotational freeform stimulator (RFS) includes both a microfluidic portion referred to as the µFS and also an electrical component. The µFS includes rotational components. The rotational components include electrodes embedded in electrolytic gel. The µFS also includes a return electrode Er embedded in gel, as well as a discharge electrolytic gel. The gels surrounding the electrodes (E1 and E2) alternate between driving current to neurons when rotated to touch the gray layer of conductive gel surrounding Er, and discharge when rotated to touch the discharge gel. Current delivered to each electrode is carefully controlled and accounted for by current sources that are operated in a control circuit via the electrical components. In some embodiments, the RFS may include more than one stimulation channel and in those instances is referred to as a multichannel freeform stimulator (MFS).
Artificial antigen presenting cells (aAPC) including a major histocompatibility class II (MHC II) molecule and methods of their use for identifying, isolating, or detecting one or more antigen-specific T cells, and treating a disease, disorder, or condition, including cancer, are disclosed.
A sensor includes a microcontroller coupled to a sensing oscillator, a reference oscillator, an environmental sensor, and a communication medium. The sensing oscillator may be less than two inches long and contain a component that changes in oscillation frequency in response to an aerosol particle, liquid-borne analyte, and/or chemical vapor attaching, depositing, and/or interacting with an outer surface of the component. The reference oscillator and environmental sensor may be used to calibrate the sensing oscillator. Data from the sensing oscillator, the reference oscillator and/or the environmental sensor is transferred to an external source by the communication medium.
Compositions and methods for the prevention and treatment of cancer and autoimmune diseases are provided which include agents which modulate the expression or function of Activins and Activin receptors. Compositions in the treatment of cancer include blockade Activin receptor 1c (AcvR1c). In one aspect, a method of modulating regulatory T cells (Tregs) in vitro or in vivo, comprises a) contacting a cell in vitro or administering to a subject an effective amount of Activin and/or an agent for modulating of Activin expression or function and/or an agent for modulating or blocking an Activin receptor (AcvR) expression or function; and b) modulating Tregs in vitro or in vivo.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A MRI-safe female bayonet for male Luer adapter for non-invasive blood pressure (NIBP) cuffs is disclosed. The MRI-safe female bayonet for male Luer adapter including a female bayonet connector comprising a housing having a removable activation structure that covers and provides access to an interior of the female bayonet connector and a resilient member that provide a bias to the removable activation structure.
Disclosed herein is a system and method for ironmaking using a comproportionation system and an electrowinning system coupled with a direct air capture system comprising an electro-synthesizer system, a carbon dioxide capture system, and a carbonation system for sequestering carbon. The system and method enables the robust processing of various iron ores, while improving the energy efficiency of iron reduction, reducing environmental impact of mining and metallurgy, and mitigating emissions associated with the whole ironmaking process.
A non-contact ultrasound tomography imaging system includes a gantry configured to accommodate at least a body part in an imaging region thereof. The gantry includes a gantry controller. The non-contact ultrasound tomography imaging system also includes an optical transmitter moveably attached to the gantry to be moveable to a plurality of positions relative to the imaging region by the gantry controller; a non-contact acoustic receiver moveably attached to the gantry to be sequentially moveable to positions relative to the optical transmitter by the gantry controlle; and an image processor configured to communicate with the non-contact acoustic receiver to receive the acoustic signal therefrom. The image processor is further configured to communicate with the gantry controller to receive position information, and the image processor is further configured to process the received acoustic signal with component position for flexible reconstruction of ultrasound transmission and reflection images.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
Provided herein are methods of determining a cognitive load of a sensorized device user in certain aspects. Provided herein are also methods of adjusting an interface between a user and a sensorized device in some aspects. Related devices, systems, and computer program products are also provided.
Provided herein are methods of determining a cognitive status of a test subject. In some embodiments, the methods include passing a test subject data set through a model that relates test subject data sets to cognitive status of the test subjects in which the model was created using reference subject data sets produced by determining three or more features from samples obtained from the reference subjects using at least a thioflavin T (ThT) assay, a dynamic light scattering (DLS) assay, and a neurotoxicity assay. In some embodiments, the methods also include outputting from the model a classification of the test subject as having a Parkinson's disease (PD) status of PD-NC (normal cognition) or PD-CI (cognitive impairment). Related systems, computer readable media, and additional methods are also provided.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G01N 33/487 - Physical analysis of biological material of liquid biological material
G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
60.
NOVEL ENDOTRACHEAL BRONCHOSCOPE SLEEVE FOR VENTILATION PROCEDURES
A broncho-sleeve for one-lung or two-lung ventilation procedures includes an elongated body having a distal end and a proximal end, the elongated body defining a lumen therein; and a bronchial cuff attached to the distal end of the elongated body. The bronchial cuff is inflatable to provide a single-lung bronchial blocker allowing one-lung ventilation when the distal end is positioned in a left or a right bronchial lumen, and to provide two-lung ventilation when the distal end is positioned in a trachea. The elongated body has an outer diameter less than 7.5 mm and an inner diameter of at least 2.8 mm.
Compositions which treat lysosomal deficits in lysosomal storage disorders, neuronal ceroid lipofuscinosis, idiopathic/sporadic brain disorders that include neurological and psychiatric disorders, include agents such as troglitazone, rosuvastatin, Compound A or the combination thereof.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
62.
ROBOTIC ASSISTANT FOR ANKLE FRACTURE WITH SYNDESMOTIC INJURY
A robotic system to assist a surgeon during ankle fracture procedures includes an imaging system configured to be at least one of mounted on or arranged adjacent to a robotic device. The system includes a passive arm, a separate actuatable section, and a controller configured to communicate with the actuatable section. The passive arm is structured to be placed on a side of a patient's leg fixed to a platform and the passive arm comprises a fastening mechanism structured to be attached to a tibia of the patient's leg. The actuatable section is structured to be placed on a side of said patient's leg fixed to the platform and the actuatable section comprises a fastening mechanism structured to be attached to a fibula of the patient's leg.
A61B 17/00 - Surgical instruments, devices or methods
A61B 17/56 - Surgical instruments or methods for treatment of bones or jointsDevices specially adapted therefor
A61B 17/88 - Methods or means for implanting or extracting internal fixation devices
A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61G 13/12 - Rests specially adapted thereforArrangements of patient-supporting surfaces
The invention provides herein epigenetics changes identified in differentially methylated regions (DMRs) of DNA of a father that are associated with the risk for an offspring having autism spectrum disorder (ASD). The invention further provides methods of determining a risk of having an offspring with ASD, methods of diagnosing ASD in a subject, and methods of determining an association between exposure to an environmental factor in a subject and an increased risk of having an offspring with ASD. The invention also provides a kit for determining whether a subject has or is at risk of having or inheriting a risk of having ASD.
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The present disclosure relates to compositions comprising prostate-specific membrane antigen (PSMA) targeted p50-IMCs and methods of using such PSMA targeted p50-IMCs.
C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Disclosed are methods for identifying and/or treating an individual having, or likely to have, acute pancreatitis. In aspects, the methods comprise detecting Elastase 2A and/or 2B in a sample obtained from the individual, for example via detection of Elastase 2A and/or 2B protein and/or an mRNA encoding Elastase 2A and/or 2B. Further disclosed are kits for detecting Elastase 2A and/or 2B.
Provided herein are methods of detecting target molecules using electrochemical sensors that comprise biomolecular receptor-bound redox reporters. Related electrochemical sensor devices, kits, systems, computer readable media, and additional methods are also provided.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
67.
COMPUTATIONAL TECHNIQUES FOR THREE-DIMENSIONAL RECONSTRUCTION AND MULTI-LABELING OF SERIALLY SECTIONED TISSUE
This document generally describes methods and systems for generating digital reconstructions of tissue from humans or other species. The method can, for example, include receiving, at a computing system, image data of a tissue sample, where one or more sections of the tissue sample are stained with hematoxylin and eosin (H&E), registering the image data to generate registered image data, identifying tissue subtypes based on application of a machine learning model to the registered image data, annotating the identified tissue subtypes to generate annotated image data, and determining a digital volume of the tissue sample in three dimensional (3D) space based on the annotated image data. The disclosed technology can provide for single-cell analysis and other analysis of tissue samples, such as early detection of cancer in human tissue samples.
G06V 10/762 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using clustering, e.g. of similar faces in social networks
68.
MRNA REGULON THERAPY FOR THE TREATMENT OF HAPLOINSUFFICIENCY DISORDERS
Described herein are compositions and methods for treatment of haploinsufficiency disorders by mRNA regulation. For example, provided herein are fusion proteins that include an RNA effector protein that targets mRNA(s) of an active allele of a gene associated with a haploinsufficiency disorder; and a regulon moiety that stimulates and/or stabilizes the mRNA(s).
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A biopsy needle accessory including a shaft with a first end, a second end, and a passageway extending between the first end and the second end. The shaft includes a circumferential wall, an aperture formed in the circumferential wall, and a ramp positioned within the passageway at the aperture. A biopsy needle is inserted through the passageway and extends through the aperture at an angle.
Compositions of hydroxyl-terminated dendrimers covalently conjugated with functional nucleic acids (D-FNA) to prevent, treat or diagnose one or more diseases or disorders in a subject in need thereof, and methods of use thereof, have been developed. Covalent conjugation of FNA to dendrimer greatly enhances serum half-life and bioavailability, protecting the payload from protein adsorption and enzymatic degradation. Preferably, the functional nucleic acids are covalently conjugated to dendrimers by functionally releasable coupling elements for intracellular release of FNAs within activated macrophages, including tumor-associated microglia (TAMs). An exemplary functionally releasable coupling element is a glutathione-sensitive coupling element. Exemplary FNAs include antisense RNAs, microRNAs and silencing RNAs. The compositions are particularly suited for treating or ameliorating symptoms of inflammatory diseases and proliferative diseases. Methods of treating a human subject having or at risk of inflammatory diseases and proliferative diseases are provided.
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
71.
ORBITAL RESILIENT BLOCKCHAIN-ENABLED INTER-AGENT TRANSACTION SERVICE PROTOCOL
Techniques for communicating between a first satellite payload in an electronic distributed ledger network and a second satellite payload in the electronic distributed ledger network are presented. The techniques include: providing, by the first satellite payload and to the distributed ledger network, a request for a service; obtaining, by the first satellite payload, a service response from the second satellite payload and an indication of compliance with a policy concerning the service; determining, by the first satellite payload, and based on the indication of compliance, whether the service response conforms to the policy concerning the service; and acting on the service response, by the first satellite payload, based on the determining.
Provided herein are methods of detecting sources of hepatitis B virus (HBV) surface antigens (HbsAgs) in samples. Some exemplary embodiments include amplifying HBV transcript nucleic acids in or from a sample and quantifying an amount of HBV transcript nucleic acids transcribed from HBV cccDNA and an amount of HBV transcript nucleic acids transcribed from the HBV iDNA. Related systems and other aspects are also provided.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
Disclosed herein are methods of detecting microbial infection in mammalian subjects comprising treatment of a sample and detection of galactofuranose (galF)-containing antigenic components utilizing monoclonal antibodies. The methods disclosed provide for pretreatment of biological samples, such as urine samples, to maximize detection of galF antigens and improvement of sensitivity of galF antigen detection assays. The methods include minimizing intelectin-1 binding to galF antigens and improvement of monoclonal antibody binding. The detection methods are useful for identifying the presence of microbial antigens related to bacterial, fungal, and parasitic pathogens, including Streptococcus pneumoniae, Aspergillus species, Fusarium species, Coccidioides species, Cryptococcus species, Histoplasma species, and Leishmania species.
A method for preparing an 18F-labeled imaging agent comprising a conjugate of a peptide having a binding specificity for programmed death ligand 1 (PD-L1) and a chelating moiety, and optionally a linker. In representative aspects, the 18F-labeled imaging agent is [18F]-DK222.
A method, computer system, and a non-transitory computer readable medium are disclosed that performs instructions including receiving, from one or more electrodes, information identifying brain activity with a stimulus artifact signal for a first time period; predicting, based on the information identifying the brain activity for the first time period, predicted brain activity without the stimulus artifact signal for a second time period that is to occur after the first time period; inserting the predicted brain activity into the information for a second time period; determining, based on the predicted brain activity for the second time period, a brain stimulus for the second time period; and causing the brain stimulus to be applied the second time period.
Degradable polymers were synthesized that self-assemble with DNA to form particles that are effective for gene delivery. Small changes to polymer synthesis conditions, particle formulation conditions, and polymer structure provides significant changes to efficacy in a cell-type dependent manner. Polymers presented here are more effective than commercially available materials, such as LIPOFECTAMINE 2000™, FUGENE®, or polyethylenimine (PEI), for gene delivery to cancerous fibroblasts or human primary fibroblasts. The presently disclosed materials may be useful for cancer therapeutics and regenerative medicine.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C07C 229/12 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
C07C 323/25 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
77.
OBTAINING EYE MOVEMENT DATA USING PATIENT-HOLDABLE DEVICE
Techniques for providing patient eye movement data using a target image displayed on a patient-holdable device are presented. The techniques include displaying a target image to a patient, where the displaying includes displaying the target image on a patient-holdable device. The techniques also include obtaining, by the patient-holdable device, patient eye movement data. The techniques further include outputting the patient eye movement data.
Machine learning system for estimating a patient prognosis based on a patient radiotracer image are presented. The techniques include: obtaining patient imaging data that includes a patient radiotracer image; providing the patient imaging data to a first trained machine learning system trained using a plurality of training images, which include: images captured using a plurality of radiotracer types, images of a plurality of cancer types, or images captured at a plurality of institutions; obtaining a first output (e.g., a segmentation or quantification) from the first trained machine learning system; generating patient feature quantifications from the first output; providing the patient feature quantifications to a second trained machine learning system trained using training feature quantifications and training prognostic data; obtaining a second output (e.g., patient prognostic data) from the second trained machine learning system; and providing a patient prognosis based on the patient prognostic data.
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G06N 3/04 - Architecture, e.g. interconnection topology
79.
IDENTIFICATION OF THERAPEUTIC TARGETS FOR BIPOLAR DISORDER
The present disclosure provides a method of evaluating a mechanism of bipolar disorder, in particular mood switch, in human-derived neurons which may include providing a mechanism of an attenuated protein interaction of CaV1.2 and BK that can cause the calcium signaling deficit, the main cellular phenotype. The present disclosure further provides a method of evaluating a composition for efficacy in treating bipolar disorder, including providing a genetically modified mouse exhibiting BK channel haploinsufficiency; administering the composition to the genetically modified non-human animal; exposing the genetically modified mouse animal to a mild stressor; and determining whether the genetically modified mouse animal experiences a behavioral switch. The present disclosure also provides a method of treating bipolar disorder in a subject in need thereof, including administering to the subject a therapeutically effective amount of a BK channel agonist.
Several methods of automatically measuring blood pressure are disclosed, which may include applying a sphygmometer cuff coupled to a transducer or detector capable of detecting an imaging signal to an extremity of a patient. The detector may include an ultrasonic or photoacoustic means of determining blood pressure. A device for automatically measuring blood pressure utilizing several methods and having a variety of configurations for obtaining blood pressure data from a patient is also disclosed.
Methods for non-invasive cancer detection use a combination of genome-wide mutation and fragmentation features of cfDNA that facilitate cancer screening.
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
82.
TESTOSTERONE AND DIFLUOROMETHYLORNITHINE COMBINATION THERAPY FOR PROSTATE CANCER
A method for treating prostate cancer by administering a first dose of a polyamine inhibitor for a first interval at a beginning of a first treatment cycle; a second dose of the polyamine inhibitor in combination with a dose of an androgen, or a derivative thereof, at a second interval during the first treatment cycle; and a dose of an antiandrogen at a third interval during the first treatment cycle is disclosed.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
A61P 13/08 - Drugs for disorders of the urinary system of the prostate
This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) suspected of having cancer. For example, this document provides methods and materials for detecting circulating tumor DNA (ctDNA) in a fluid sample (e.g., a fluid sample containing cfDNA) obtained from a mammal (e.g., a human) suspected of having cancer. In some cases, this document provides methods and materials for assessing and, optionally, treating a mammal having cancer. For example, a mammal (e.g., a human) identified as having the presence of ctDNA in a fluid sample (e.g., a fluid sample containing cfDNA) obtained from the mammal can be administered one or more cancer treatments.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A device for detection and identification of suspended particles by functional groups of the particles includes a first detector element, a second detector element, and a processor configured to communicate with the first and second detector elements. The first detector element and second detector element includes a first electrode, a second electrode space apart from the first electrode, and a first organic semiconducting layer extending between and in contact with the first and second electrodes. The first and second organic semiconducting layers differ in at least one of chemical composition or morphology so as to have different electrical responses to different functional groups of particles to be detected, and the processor is configured to indicate a detection and identification of the suspended particles by functional groups of the particles based on the different electrical responses to different functional groups of particles to be detected.
G01N 27/414 - Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
H01L 29/08 - Semiconductor bodies characterised by the shapes, relative sizes, or dispositions of the semiconductor regions with semiconductor regions connected to an electrode carrying current to be rectified, amplified, or switched and such electrode being part of a semiconductor device which comprises three or more electrodes
A photoacoustic system for tissue-conserving surgery includes a photoacoustic transmitter, an acoustic receiver arranged to receive acoustic energy from a photoacoustic source generated within a surgical region of a patient by the photoacoustic transmitter, and a data processor configured to communicate with the acoustic receiver. The photoacoustic transmitter is configured to be insertable into a resection cavity of the surgical region of the patient during the tissue-conserving surgery. The photoacoustic transmitter includes a light source that emits light that is absorbed more strongly by a contrast agent than surrounding tissue, the contrast agent being suitable to selectively concentrate more in cancerous tissue than in healthy tissue, and the processor is further configured to provide a location of the photoacoustic source when generated in at least a portion of the contrast agent by the photoacoustic transmitter.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (USA)
Inventor
Fu, Dax
Yu, Liping
Guo, Zheng
Abstract
The present invention relates to the field of immunology. More specifically, the present invention provides methods and compositions directed to the use of antibodies to the pancreatic zinc transporter, ZnT8. In particular embodiments, the anti-ZnT8 antibodies specifically bind the transmembrane domain of ZnT8. In more specific embodiments, the anti-ZnT8 antibodies specifically the extracellular surface of the transmembrane domain.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
An antenna assembly may include a shape change antenna configured to transmit an electromagnetic wave or receive an electromagnetic wave. The shape change antenna may have an antenna shape and may be formed of a conductive shape memory material that physically moves in response to changes in a non-geometric characteristic. The antenna assembly may also include a shape change stimulator configured to change the non-geometric characteristic of the shape change antenna to cause the antenna shape to physically change between a first geometry and a second geometry.
H01Q 3/01 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the shape of the antenna or antenna system
88.
MODIFIED REDOX-ACTIVE SORBENTS FOR ELECTROCHEMICAL CARBON DIOXIDE SEPARATION
Isoindigo derivatives and their use as sorbents for the electrochemically mediated carbon capture (EMCC) reversible CO2 capture and release are disclosed.
B01D 53/32 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
B01D 53/04 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
B01J 20/22 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising organic material
The present disclosure provides methods for sorting retinal cells for use in cellular component transfer therapy, sorted populations of retinal cells generated by such methods, and compositions comprising such sorted populations of retinal cells. The present disclosure also provides uses of sorted populations of retinal s and compositions comprising thereof for preventing and/or treating inherited retinal degenerative diseases.
A method of inhibiting viral replication of a virus in an individual comprising administering an effective amount of a drug nanosuspension combined with a surfactant, wherein the drug nanosuspension combined with the surfactant is delivered to the individual's lungs. Preferably, the drug is a nanosuspension delivered to the individual's lungs through inhalation.
A method includes receiving a diffusion weight image (DWI), a structural T1 image, or both from a magnetic resonance imaging (MRI) sequence on a patient's brain. The patient suffers from drug-resistant mesial temporal epilepsy (mTLE). The method also includes generating an apparent diffusion coefficient (ADC) map of the patient's brain based at least partially upon the DWI, the structural T1 image, or both. The method also includes segmenting one or more mesial temporal lobe portions from a remainder of the patient's brain based at least partially upon the ADC map. The method also includes identifying one or more clusters to be ablated in the one or more mesial temporal lobe portions.
A61B 18/20 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
92.
RO52 TARGETING ANTIBODY OR ANTIGEN BINDING FRAGMENTS THEREOF FOR USE IN TREATING CANCER
Provided herein are methods of treating a cancer in a subject, wherein the cancer expresses a Ro52 antigen, comprising administering an anti-Ro52 binding agent to the subject, thereby treating the cancer in the subject. In some embodiments, the Ro52 antigen is expressed on a cancer cell surface. In some embodiments, the anti-Ro52 binding agent comprises a Fab, Fab', F(ab')2, Fahl-SH, Fv, diabody, linear antibody or single-chain variable fragment (scFv). In some embodiments, the anti-Ro52 binding agent is a humanized or chimeric antibody. In some embodiments, the anti-Ro52 binding agent is conjugated to a therapeutic agent.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The disclosure provides herein extracellular vesicles that can preferentially bind to and/or be taken up by certain populations of blood cells, e.g., B cells. The disclosure further provides methods of using compositions of extracellular vesicles to target B cells. Also provided herein are methods of using compositions of extracellular vesicles as a therapeutic strategy for B cell diseases. In some embodiments, the present disclosure provides a method of treatment of a B cell disease in a subject including: administering a composition including extracellular vesicles to the subject in need thereof, thereby treating the disease.
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
94.
ELECTROCHEMICAL CAPTURE OF CARBON DIOXIDE FROM AIR WITH ELECTRICITY STORAGE
Machine learning techniques of characterizing senescence in an immobilized patient cell are disclosed. The techniques include: obtaining a patient cell image; passing the patient cell image to a trained machine learning system, where the trained machine learning system is trained using a training corpus that includes a plurality of training cell images, where the plurality of training cell images include a plurality of images of normal cells and a plurality of images of cells with senescence; obtaining an output from the trained machine learning model in response to the passing, where the output is indicative of a senescence property of the patient cell, and where the senescence property is non-binary; and providing an indication of the senescence property of the patient cell based on the output.
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) used to treat a condition or disease that is associated with hypoxia, or with increased expression of hypoxia-inducible factor HIF-1 and/or HIF-2, or with both, the method comprising administering to a subject in need of such treatment a compound of Formula (I) that is capable of inhibiting transcriptional activation mediated by HIFs. This disclosure also features compositions containing the same as well as methods of using and making the same.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (USA)
Inventor
Falco, Gregory
Siegel, Joshua
Abstract
A method of creating a virtual asset based on an existing real-world asset is disclosed. The method includes digitally sequencing the existing real-world asset to create a digital sequence of the real-world asset; tokenizing the digital sequence of the real-world asset to create a tokenized digital sequence; associating the tokenized digital sequence with the real-world asset; and creating a title of ownership of the tokenized digital sequence.
A method for performing a screening includes illuminating a sample with light from a screen of a system at a first wavelength while the system is at a predetermined position with respect to the sample. The method also includes capturing a first image of the sample using a camera of the system while the system is at the predetermined position and the sample is illuminated with the light at the first wavelength. The method also includes illuminating the sample with the light from the screen at a second wavelength while the system is at the predetermined position. The method also includes capturing a second image of the sample using the camera while the system is at the predetermined position and the sample is illuminated with the light at the second wavelength. The method also includes combining the first and second images to produce a multispectral image.
Disclosed herein are immune activating conjugates with immunogenic carrier proteins coupled to hapten and immune cell receptor agonist-containing polymers. The polymers promote uptake by B cells, enabling intracellular immune cell receptor activation and formation of long-lived antibody-secreting cells. In some aspects, disclosed herein in is a conjugate comprising an immunogenic carrier protein coupled to a polymer, wherein the polymer includes: i) a first monomeric unit comprising a first monomer coupled to a hapten, and ii) a second monomeric unit comprising a second monomer coupled to an immune cell receptor agonist.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/385 - Haptens or antigens, bound to carriers
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Techniques for label-free determination of a value a blood property are presented. The techniques may utilize a device that includes an optical objective with at least one lens; a first light source situated so as to provide first light to a body part; a first electronic detector situated to receive light gathered by the optical objective and generate image data, where, at the optical objective, a central axis of the first light is not parallel to a central axis of light that passes to the first electronic detector; an electronic processor communicatively coupled to the first electronic detector and configured to determine the value of the blood property based at least in part on the image data; and an output interface communicatively coupled to the at least one electronic processor and configured to provide the value of the blood property.
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
G01N 15/01 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
